Racotumomab–alum vaccine for the treatment of non-small-cell lung cancer

Racotumomab–alum vaccine is an anti-idiotypic  https://168pg.net/  vaccine capable of mimic the tumor-associated antigen NeuGcGM3. Different Phase I scientific trials and compassionate use research verified its low toxicity and capability to induce a strong anti-NeuGcGM3 reaction, capable of bind and directly kill tumor cells expressing the antigen. A Phase II/III randomized double-blind clinical trial in superior non-small cell lung cancer sufferers showed a large improvement in universal survival and development-loose survival for racotumomab–alum as opposed to placebo. Patients who evolved anti-NeuGcGM3 antibodies capable of binding and killing NeuGcGM3 expressing tumor cells confirmed considerably longer median survival instances. The impact of using racotumomab–alum as transfer renovation accompanied with the aid of 2d-line remedy is currently being explored in a brand new randomized, multinational Phase III take a look at.

Keywords: anti-idiotypic antibodyclinical trialNeuGcGM3NSCLCvaccine
Previous article
View difficulty desk of contents
Next article
Financial & competing pastimes disclosure
AM Vázquez is the inventor of patents associated with racotumomab; however, she assigned her rights to the assignee Center of Molecular Immunology. The authors have no other relevant affiliations or economic involvement with any enterprise or entity with a financial hobby in or economic warfare with the concern count or materials discussed in the manuscript aside from the ones disclosed.

Key troubles
Non-small-cell lung most cancers (NSCLC) remains the most not unusual purpose of cancer-related loss of life.

NeuGc gangliosides are attractive goals for NSCLC immunotherapy since they’re now not evidently expressed in ordinary human tissues but had been detected in NSCLC patients’ samples.

The anti-Id vaccine racotumomab–alum is capable of elicit a strong and precise antibody response against NeuGcGM3, capable of apprehend and directly kill tumor cells expressing the antigen.

A Phase II/III randomized double-blind scientific trial with stage IIIb/IV NSCLC sufferers who’ve at least solid disease after first-line chemotherapy showed a giant increase inside the OS and progressed 2-year survival rates for the racotumomab–alum group in comparison with the placebo institution.

Among the vaccinated sufferers, substantially longer survival instances were accomplished by using folks that elicited IgM antibodies able to understand as a minimum 20% or kill at the least 25% of NeuGcGM3-advantageous tumor cells.

To verify those effects a randomized Phase III clinical trial in advanced NSCLC sufferers is ongoing, in which primary endpoint is OS.

More Share Options

Related research
People additionally read
Recommended articles
Cited with the aid of
Alum: an vintage dog with new tricks
Yumei Wen et al.
Emerging Microbes & Infections
Published online: 25 Jan 2019
Browse journals by using subject
Back to pinnacle
Area Studies
Behavioral Sciences
Built Environment
Communication Studies
Computer Science
Earth Sciences
Economics, Finance, Business & Industry
Engineering & Technology
Environment & Agriculture
Environment and Sustainability
Food Science & Technology
Global Development
Health and Social Care
Information Science
Language & Literature
Mathematics & Statistics
Medicine, Dentistry, Nursing & Allied Health
Museum and Heritage Studies
Physical Sciences
Politics & International Relations
Social Sciences
Sports and Leisure
Tourism, Hospitality and Events
Urban Studies
Information for
R&D experts
Open access
Open journals
Open Select
Dove Medical Press
Reprints and e-prints
Advertising solutions
Accelerated booklet
Corporate get admission to answers
Help and information
Help and make contact with
All journals
Keep updated
Register to get hold of customized research and sources with the aid of e mail
Sign me up
Taylor and Francis Group Facebook pageTaylor and Francis Group Twitter pageTaylor and Francis Group Linkedin web page
Taylor and Francis Group Youtube pageTaylor and Francis Group Weibo web page
Copyright © 2022 Informa UK Limited Privacy coverage Cookies Terms & conditions Accessibility
Registered in England & Wales No. 3099067
5 SW1P 1WG

Taylor and Francis Group
We use cookies to enhance your internet site revel in. To find out about our use of cookies and the way you can manage your cookie settings, please see our Cookie Policy. By closing this message, you’re consenting to our use of cookies.


Leave a comment

Your email address will not be published.